您的购物车当前为空
EtDO-P4是一种细胞可渗透的强效神经酰胺类似物,作为 UDP-葡萄糖神经酰胺葡萄糖基转移酶(UGCG)的高选择性纳米摩尔级抑制剂,可阻断鞘糖脂(GSLs)的合成。通过降低细胞膜上GSLs的水平,抑制EGFR诱导的ERK信号通路及多种受体酪氨酸激酶 (RTKs)的活化,在多种肿瘤模型中展现出抗增殖活性。此外,EtDO-P4 还被报道可降低化疗耐药性并增强传统抗癌药物(如长春新碱、顺铂)的细胞毒性。
EtDO-P4是一种细胞可渗透的强效神经酰胺类似物,作为 UDP-葡萄糖神经酰胺葡萄糖基转移酶(UGCG)的高选择性纳米摩尔级抑制剂,可阻断鞘糖脂(GSLs)的合成。通过降低细胞膜上GSLs的水平,抑制EGFR诱导的ERK信号通路及多种受体酪氨酸激酶 (RTKs)的活化,在多种肿瘤模型中展现出抗增殖活性。此外,EtDO-P4 还被报道可降低化疗耐药性并增强传统抗癌药物(如长春新碱、顺铂)的细胞毒性。

| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 2 mg | ¥ 468 | 现货 | |
| 25 mg | ¥ 4,150 | 8-10周 | |
| 50 mg | ¥ 5,390 | 8-10周 | |
| 100 mg | ¥ 9,150 | 8-10周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | EtDO-P4 is a cell-permeable, potent ceramide analogue that acts as a highly selective nanomolar inhibitor of UDP-glucose ceramide glucosyltransferase (UGCG), blocking glycosphingolipid (GSL) synthesis. By reducing GSL levels on cell membranes, it inhibits EGFR-induced ERK signaling and the activation of various receptor tyrosine kinases (RTKs), demonstrating anti-proliferative activity in multiple tumor models. Additionally, EtDO-P4 has been reported to reduce chemotherapy resistance and enhance the cytotoxicity of conventional anticancer drugs (such as vincristine and cisplatin). |
| 分子量 | 516.76 |
| 分子式 | C31H52N2O4 |
| CAS No. | 245329-78-6 |
| Smiles | [C@@H]([C@@H](CN1CCCC1)NC(CCCCCCCCCCCCCCC)=O)(O)C=2C=C3C(=CC2)OCCO3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 80 mg/mL (154.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。 | ||||||||||||||||||||||||||||||||||||
对于不同动物的给药剂量换算,您也可以参考 更多